FWPFWP
Oct 15, 2026Free writing prospectus0001493152-26-047185
Sources: sec-edgar, sec-harvest
No live market is quoted for Interpace Biosciences Inc yet. Get in line for IPO-day access through a broker in the meantime.
Invest in stocks once they list with eToro
Trade stocks, ETFs and crypto from one simple account.
From SEC filings, latest FY ending Dec 31, 2025 · CIK 0001054102.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $38.73M | $46.93M | $40.04M | $31.84M | $33.12M |
| Gross profit | $24.13M | $29.93M | $25.06M | $18.23M | $18.8M |
| Operating income | $4.08M | $8.11M | $3.96M | -$3.62M | -$6.34M |
| Net income | $24.6M | $6.7M | $2M | -$21.96M | -$14.94M |
| R&D expense | $642K | $676K | $636K | $703K | $1.49M |
| Cash & equivalents | $2.51M | $1.46M | $3.5M | $4.83M | $2.67M |
| Total assets | $33.84M | $14.79M | $13.12M | $15.98M | $38.43M |
| Total liabilities | $11.48M | $17.01M | $22.12M | $32.52M | $34.31M |
| Shareholders' equity | $22.36M | -$2.22M | -$55.54M | -$58.09M | -$42.42M |
EDGAR filings resolved from IDXG / CIK 0001054102.